1 / 1

Epidermolysis Bullosa Market

In 2017, the total prevalent population of Epidermolysis Bullosa in 7MM was 41,509. The prevalent cases of Epidermolysis Bullosa in the United States was 26,104 in 2017, while the United Kingdom and Germany had 5,037 and 4,919 prevalent cases respectively. <br><br>The market size of Epidermolysis Bullosa in 7MM USD 2,283.40 million in 2017. <br><br>Robust pipeline, increase in funding for accelerating the development of novel therapies for Epidermolysis Bullosa treatment and encouraging organizations to develop promising therapies are some of the key factors expected to drive the Epidermolysis Bullosa Market forward in the coming years. <br><br>The key players in the Epidermolysis Bullosa Market includes Amryt Pharma, Abeona Therapeutics, Castle Creek Pharmaceuticals, RegeneRx, Krystal Biotech, Fibrocell Technologies, Castle Creek Pharmaceuticals, RHEACELL GmbH, Holostem Terapie Avanzate, StemRim, Shionogi, Menlo Therapeutics and Phoenix Tissue Repair. <br><br>For more detailed information on Epidermolysis Bullosa Market, visit:<br>https://www.delveinsight.com/report-store/epidermolysis-bullosa-market<br><br>

DelveInsight
Download Presentation

Epidermolysis Bullosa Market

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

    More Related